Boeing
BA
$177.00
+2.13%
Boeing is a global aerospace and defense manufacturer operating three segments: Commercial Airplanes (competing with Airbus in the 130+ seat market), Defense, Space & Security (competing with Lockheed Martin and Northrop Grumman on military aircraft, satellites, and weapons), and Global Services, which provides aftermarket support to airlines worldwide. As one of only two dominant Western commercial aircraft OEMs, Boeing is a duopoly participant with immense barriers to entry, a massive installed base, and a backlog that spans years, but its competitive identity has been defined by execution risk rather than market power in recent years. The current investor narrative is a high-stakes turnaround story: the October 2026 earnings report triggered an 11% single-day plunge on lower production rates and missed delivery targets, resetting expectations around cash flow timing, even as the FAA certification of the 737 MAX 10 removes a major overhang and a more contractor-friendly Pentagon posture offers a potential defense rerating. Bulls point to management's 2029 cash targets and a strong buy consensus, while bears focus on persistent negative free cash flow, a leveraged balance sheet, and the repeated pattern of operational promises slipping to the right.…
BA
Boeing
$177.00
Related headlines
Investment Opinion: Should I buy BA Today?
Rating: Hold with a speculative-recovery bias. The core thesis is that Boeing's duopoly franchise, a $233.35 average analyst target implying +34.6% upside from $173.31, and a 25-Buy/0-Sell consensus are real, but they are contingent on a cash-flow inflection that has slipped yet again after the October 2026 earnings reset — so investors are being asked to pay today for a 2027-2029 recovery that has not yet shown up in reported results. The 1.43 mean rating (strong_buy) and the absence of any downgrades on October 28-29, 2026 anchor the view that institutional conviction remains intact even as the stock sits at just 9.3% of its 52-week range.
The supporting evidence is a mix of genuine improvement and unresolved fragility. On the positive side, Q3 2026 revenue of $24.19B grew 3.94% YoY, gross margin of 8.96% is a dramatic swing from the -10.21% posted in Q3 2025, and the net loss narrowed to -$116M from -$444M in Q2 2026. FAA certification of the 737 MAX 10 removes a multi-year overhang, and Global Services ($5.57B in Q3 revenue) provides recurring aftermarket revenue that is far less execution-sensitive than new deliveries. Against that, trailing free cash flow is -$1.54B, debt-to-equity is 9.98x, interest coverage is 0.24 with Q3 interest expense of $573M exceeding operating income of $139M, and the forward PE of 80.1x on estimated EPS of $11.95 versus trailing EPS of $0.0135 prices a step-change in profitability that has not appeared. The 1.85x PS multiple is below the historical 4.5x-8.3x band, but that reflects compressed margins rather than a clean discount.
The biggest risks that could invalidate the thesis are (1) another delivery-rate reset that pushes the 2027 cash inflection out again, (2) a break below the $165.01 52-week low that triggers momentum selling toward the $157.00 analyst low, and (3) a balance-sheet event — another equity or debt raise — given the 9.98x leverage and negative free cash flow. This Hold would upgrade to Buy if free cash flow inflects positive on a trailing basis or if the stock holds $165 and management confirms delivery cadence on the next earnings call; it would downgrade to Sell if deliveries miss again or if the 2029 cash targets are formally deferred. Valuation verdict: fairly valued to modestly undervalued on sales (1.85x PS) but expensive on earnings and cash flow — a value-trap-or-deep-value setup that depends entirely on execution, not on the multiple.
Sign up to view all
BA 12-Month Price Forecast
The forward view is genuinely two-sided: the sell-side is overwhelmingly bullish (1.43 mean rating, zero Sells, +34.6% implied upside), but the reported financials still show cash burn, heavy leverage, and interest expense exceeding operating income, and the stock has underperformed SPY by 25.66% over one year. The 50% base case assumes gradual recovery toward the $233.35 average target, but the wide $157-$305 target range (nearly 2x) signals that even the bulls disagree on timing. I would upgrade to bullish if trailing free cash flow turns positive or if deliveries beat on the next report while holding the $165.01 support; I would downgrade to bearish if the 2029 cash targets are deferred or if the stock breaks $165.01 on volume. Until then, the risk/reward is balanced but the burden of proof sits squarely on management's execution.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Boeing's 12-month outlook, with a consensus price target around $233.35 and implied upside of +31.8% versus the current price.
Average Target
$233.35
28 analysts
Implied Upside
+31.8%
vs. current price
Analyst Count
28
covering this stock
Price Range
$157 - $305
Analyst target range
Coverage is deep and overwhelmingly bullish: 26 analysts rate the stock, with 25 Buy, 3 Hold, and 0 Sell, producing a consensus recommendation of "strong_buy" and a mean rating of 1.43 (where 1.0 is a strong buy). The average target price of $233.35 implies roughly +34.6% upside from the current $173.31, a striking disconnect given the stock's 27.84% three-month decline and the recent earnings miss. The consensus is clearly leaning bullish, and the institutional ratings flow confirms conviction rather than drift: on October 28-29, 2026, Bernstein, JP Morgan, TD Cowen, Barclays, UBS, RBC, Wells Fargo, Jefferies, BNP Paribas, and Susquehanna all reiterated Outperform/Buy/Overweight/Positive ratings, with no downgrades in the visible data. The target range is wide, from a low of $157.00 (about -9.4% downside) to a high of $305.00 (about +76.0% upside), a spread of nearly 2x that signals high uncertainty about the timing and magnitude of the recovery. The high target assumes successful production ramp, MAX 10 cash flow materialization by 2027, defense contract tailwinds, and multiple expansion toward historical norms, while the low target prices in continued execution slippage, margin compression, and cash burn extending beyond current guidance. The estimated EPS average of $11.95 (range $11.34-$12.65) and revenue average of $146.0 billion (range $140.3-$152.6 billion) show analysts expect a sharp earnings recovery from the current near-zero base, which is the crux of the bull case and the key risk if delivery targets slip again.
Drowning in data?
Find the real signal!
Bulls vs Bears: BA Investment Factors
The bear case currently has stronger near-term evidence: negative free cash flow of -$1.54B, debt-to-equity of 9.98x, interest expense exceeding operating income, and a stock down 27.84% in three months that just gapped 11% lower on missed delivery targets. The bull case rests on forward-looking, unproven items — a 2029 cash target, MAX 10 cash flow materializing in 2027, and a $233.35 analyst target implying +34.6% upside — backed by a 25-Buy/0-Sell consensus that has so far failed to arrest the decline. The single most important tension is whether management's 2029 cash targets are credible after yet another production-rate reset; if delivery cadence reaccelerates and free cash flow inflects positive in 2027, the depressed 1.85x PS multiple re-rates sharply, but if slippage continues, the stock breaks the $165.01 support and the value-trap thesis wins. Until there is tangible evidence of cash inflection rather than reiterated targets, the weight of current data favors caution over conviction.
Bullish
- Analyst consensus overwhelmingly bullish: 25 of 26 covering analysts rate BA a Buy with zero Sells, producing a 'strong_buy' consensus and a mean rating of 1.43. The $233.35 average target implies +34.6% upside from $173.31, and ten-plus firms (Bernstein, JPMorgan, UBS, Barclays, Jefferies) reiterated Outperform ratings on October 28-29, 2026 with no downgrades visible.
- MAX 10 certification removes key overhang: FAA certification of the 737 MAX 10 in late October 2026 eliminates a multi-year regulatory overhang and unlocks near-term cash flow and margin expansion expected to materialize by 2027. This is a concrete de-risking event that directly supports the bull case for the 2027-2029 cash inflection.
- Duopoly franchise with massive backlog: Boeing is one of only two dominant Western commercial aircraft OEMs, competing with Airbus in the 130+ seat market, with an installed base and multi-year backlog that create immense barriers to entry. Global Services ($5.57B in Q3 2026) provides recurring aftermarket revenue that is far less execution-sensitive than new aircraft deliveries.
- Revenue growth and margin recovery off trough: Q3 2026 revenue of $24.19B rose 3.94% YoY, and gross margin of 8.96% is a dramatic improvement from the -10.21% gross margin in Q3 2025, when the company posted a -$5.34B net loss. Net loss narrowed to -$116M in Q3 2026 from -$444M in Q2 2026, showing sequential progress toward breakeven.
Bearish
- Persistent negative free cash flow: Trailing free cash flow is -$1.54B, meaning the company is still burning cash and relying on its $9.54B cash balance rather than internal generation. The PCF ratio of 155.4x and cash flow coverage ratio of 0.033 underscore how thin cash generation is relative to enterprise value and debt service needs.
- Leveraged balance sheet, weak coverage: Debt-to-equity stands at 9.98x with a thin current ratio of 1.19, and interest coverage of just 0.24 in the latest quarter means operating cash flow covers only a fraction of interest expense. Q3 2026 interest expense of $573M alone exceeds the $139M operating income, so the company is effectively borrowing to service debt.
- Falling-knife technical breakdown: At $173.31 the stock sits at just 9.3% of its 52-week range ($165.01-$254.35), down 27.84% over three months versus SPY's -2.01%, with relative strength of -25.83% over that period. The October 27 gap from $188.31 to $168.18 on the earnings miss shows company-specific catalysts, not macro, are driving the selloff, and support at $165.01 is only 4.8% below.
- Execution slippage keeps repeating: The October 2026 earnings report triggered an 11% single-day plunge on lower production rates and missed delivery targets, resetting cash flow timing expectations. This fits a repeated pattern of operational promises slipping to the right, which directly undermines the credibility of management's 2029 cash targets that underpin the bull case.
BA Technical Analysis
Boeing is in a sustained downtrend, with the stock down 15.27% over the past year and 23.91% year-to-date, badly lagging the S&P 500's +10.39% and +10.62% respective returns. At a current price of $173.31, the stock sits at just 9.3% of its 52-week range of $165.01 to $254.35, meaning it is trading near the very bottom of its annual band after a steady sequence of lower highs. This positioning signals a falling-knife setup rather than a value opportunity: the stock has lost roughly a third of its value from its peak, with a max drawdown of -33.71%, and momentum remains firmly negative. The relative strength figures confirm the underperformance is structural, not market-driven, with -25.66% relative weakness versus SPY over one year and -34.53% YTD. Short-term momentum is accelerating to the downside: the stock is down 10.46% over the past month versus SPY's -1.99%, down 27.84% over three months versus SPY's -2.01%, and down 24.98% over six months versus SPY's +3.11%. The 1-month decline (-10.46%) is steeper than the 3-month (-27.84%) and 1-year (-15.27%) figures on an annualized basis, indicating the selloff intensified after the late-October earnings miss, when the stock gapped from $188.31 on October 26 to $168.18 on October 27. This divergence from the broader market—relative strength of -8.47% over just one month—signals that company-specific catalysts, not macro conditions, are driving the price action, and there is no evidence of capitulation volume or a momentum trough yet. Key technical levels are clear: support sits at the 52-week low of $165.01, just 4.8% below the current $173.31, and a breakdown below that level would likely trigger further momentum selling and open a new leg lower. Resistance is anchored at the 52-week high of $254.35, roughly 46.8% above current levels, with intermediate resistance around the $188-$192 area where the stock traded before the October gap. With a beta of 1.331, Boeing is about 33% more volatile than the market, meaning position sizing should account for amplified drawdowns; combined with a short ratio of just 0.02 (negligible short interest), the selling appears to be long-only de-risking rather than a crowded short squeeze setup.
Beta
1.33
1.33x market volatility
Max Drawdown
-33.7%
Largest decline past year
52-Week Range
$165-$254
Price range past year
Annual Return
-10.6%
Cumulative gain past year
| Period | BA Return | S&P 500 |
|---|---|---|
| 1m | -8.2% | -1.0% |
| 3m | -23.8% | -0.2% |
| 6m | -25.4% | +4.0% |
| 1y | -10.6% | +13.6% |
| ytd | -22.3% | +12.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BA Fundamental Analysis
Revenue is growing but modestly and unevenly: Q3 2026 revenue of $24.19 billion rose 3.94% year-over-year, continuing a multi-quarter expansion from $22.22 billion in Q1 2026 and $24.56 billion in Q2 2026, with the Q3 figure slightly below Q2. Segment data shows Commercial Airplanes at $10.72 billion, Defense, Space & Security at $7.94 billion, and Global Services at $5.57 billion, with commercial aircraft the largest but most execution-sensitive driver. The growth trend is positive but decelerating relative to what a recovery story needs, and the October production-rate cuts suggest near-term revenue upside is capped; the investment case hinges on whether delivery cadence can reaccelerate toward management's 2029 targets rather than on current top-line momentum. Profitability remains fragile: Q3 2026 net income was -$116 million (EPS -$0.26), an improvement from Q2's -$444 million but a reversal from Q1's near-breakeven -$4 million, and gross margin compressed to 8.96% from 11.46% in Q1 and 9.83% in Q2. The trailing net margin is just 2.50% and the operating margin 4.79%, both far below what a duopoly aerospace OEM should earn at scale, reflecting production inefficiencies, rework costs, and fixed-cost absorption issues. The trajectory is mixed rather than cleanly improving: the company swung to a massive $8.22 billion net profit in Q4 2025 on a $9.13 billion non-operating gain, which flatters trailing figures, while the underlying operating loss of -$815 million that quarter shows core profitability has not normalized. Balance sheet risk is the central concern: debt-to-equity stands at 9.98x, the current ratio is a thin 1.19, and trailing free cash flow is -$1.54 billion, meaning the company is still burning cash and dependent on its $9.54 billion cash balance and investment portfolio rather than internal generation. ROE of 40.98% is distorted by a small, negative-trending equity base and should not be read as a quality signal, while ROA of -0.11% confirms the asset base is not producing returns; the cash flow coverage ratio of 0.033 and interest coverage of 0.24 in the latest quarter underscore how little operating cash flow is available to service a heavy debt load.
Quarterly Revenue
$24.2B
2026-09
Revenue YoY Growth
+3.9%
YoY Comparison
Gross Margin
9.0%
Latest Quarter
Free Cash Flow
$-1.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BA Overvalued?
Because trailing net income is marginally positive (EPS $0.0135) but economically meaningless and distorted by one-time items, the PE ratio of 87.2x is not a reliable anchor; the forward PE of 80.1x on estimated EPS of $11.95 is more informative but still reflects a market pricing a multi-year earnings recovery rather than current profitability. The gap between trailing and forward earnings power is enormous, implying the market expects a step-change in profitability that has not yet appeared in reported results, which makes the valuation highly sensitive to execution. On sales-based metrics, the PS ratio of 1.85x and EV/Sales of 1.74x are more grounded, though EV/EBITDA of 28.4x and a PCF ratio of 155.4x highlight how thin current cash generation is relative to enterprise value. Peer comparison is difficult because Boeing's margins are far below aerospace and defense norms: a gross margin of 4.79% and operating margin of 4.79% compare poorly with defense primes that typically earn double-digit operating margins, so the 1.85x PS multiple is not obviously cheap on a quality-adjusted basis. The PB ratio of 30.3x is extreme and reflects a near-zero or negative book equity base rather than premium franchise value, and the negative PEG ratio of -0.77 is not meaningful given the earnings base. Against its own history, the stock's PS ratio has ranged from roughly 4.5x to 8.3x over the past several years, and the current 1.85x is well below that band—but this reflects a much larger revenue base and compressed margins rather than a clean valuation discount. The market is pricing Boeing at a depressed multiple on depressed earnings, which is either a deep-value setup or a value trap depending on whether cash flow inflects; the historical PE band is unusable given the string of losses, so investors should anchor on normalized free cash flow and the credibility of the 2029 targets.
PE
87.2x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
39.4x
Industry PE ~39.4x*
EV/EBITDA
28.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are acute and quantifiable. Trailing free cash flow is -$1.54B, debt-to-equity is 9.98x, and the current ratio of 1.19 leaves little liquidity cushion, while Q3 2026 interest expense of $573M dwarfs operating income of $139M and interest coverage sits at 0.24. Gross margin of 8.96% in Q3 2026 has compressed from 11.46% in Q1 2026, and the company's profitability is heavily concentrated in Commercial Airplanes ($10.72B of $24.19B Q3 revenue), making the entire thesis hostage to 737 production cadence and delivery execution. The Q4 2025 net profit of $8.22B was driven by a $9.13B non-operating gain, not operations — the underlying operating loss that quarter was -$815M — so trailing figures flatter the true earnings power.
Market and competitive risks center on valuation compression and relative underperformance. At a forward PE of 80.1x and EV/EBITDA of 28.4x, Boeing trades at a premium that assumes a multi-year earnings recovery, leaving little room for disappointment; a beta of 1.331 means drawdowns are amplified roughly 33% versus the market. The stock has underperformed SPY by 25.66% over one year and 34.53% YTD, and the October 27 gap lower on production cuts shows company-specific catalysts dominate price action. Competitive pressure from Airbus in commercial aircraft and from Lockheed Martin and Northrop Grumman in defense — where Lockheed's backlog is described as soaring on high-margin missiles — limits Boeing's ability to price for margin recovery, while the contractor-friendly Pentagon shift is a sector-wide tailwind rather than a Boeing-specific edge.
The worst-case scenario is a chain of continued delivery slippage, a break below the $165.01 52-week low, and a deferral of the 2029 cash targets that forces another equity or debt raise, further diluting a balance sheet already at 9.98x debt-to-equity. From the current $173.31, a move to the 52-week low of $165.01 represents about -4.8%, but the analyst low target of $157.00 implies roughly -9.4% downside, and the stock's max drawdown of -33.71% shows how far it can fall in a sustained de-rating. In a severe scenario where free cash flow remains negative through 2027 and the multiple compresses toward the low end, a decline of 20-30% from current levels (roughly $121-$139) is plausible, consistent with the magnitude of the recent drawdown.
FAQ
The most severe risk is financial: trailing free cash flow of -$1.54B, debt-to-equity of 9.98x, a current ratio of 1.19, and interest coverage of 0.24 mean the balance sheet, not demand, is the binding constraint, and another equity or debt raise would dilute shareholders. Second is execution risk: the October 2026 earnings report triggered an 11% single-day plunge on lower production rates and missed delivery targets, continuing a pattern of operational promises slipping right and directly threatening the 2029 cash targets that underpin the bull case. Third is valuation compression: at 80.1x forward PE and 28.4x EV/EBITDA, there is little room for disappointment, and with a beta of 1.331 drawdowns are amplified roughly 33% versus the market — the stock has already underperformed SPY by 25.66% over one year. Fourth is competitive and company-specific: Airbus pricing pressure limits margin recovery in commercial aircraft, while Lockheed Martin and Northrop Grumman compete aggressively in defense, and the stock sits just 4.8% above its $165.01 52-week low with negligible short interest (0.02), meaning selling is long-only de-risking that could accelerate on a breakdown.
The 12-month forecast splits into three scenarios. The base case (50% probability) targets $200-$233.35, assuming revenue tracks the $146.0B consensus, gross margin improves gradually from 8.96%, and free cash flow approaches breakeven by late 2027, converging toward the $233.35 average analyst target. The bull case (25%) targets $254.35-$305.00, requiring delivery reacceleration, MAX 10 cash flow materializing on schedule, positive free cash flow, and a Pentagon-driven defense rerating that re-rates the depressed 1.85x PS multiple. The bear case (25%) targets $157.00-$165.01, driven by another delivery slippage, a break of the 52-week low, and a financing event forcing dilution. The base case is most likely, and its key assumption is that management's 2029 cash targets remain credible and delivery cadence stabilizes rather than resets again — the wide $157-$305 range (nearly 2x) shows even the bulls disagree on timing.
The answer depends entirely on which metric you anchor to. On sales, BA looks cheap: the 1.85x PS and 1.74x EV/Sales sit well below the stock's historical 4.5x-8.3x band, but that discount reflects compressed margins (8.96% gross, 4.79% operating) rather than a clean bargain, since a larger revenue base at thin margins deserves a lower multiple. On earnings and cash flow, it looks expensive: the 80.1x forward PE on estimated EPS of $11.95 versus trailing EPS of $0.0135, the 28.4x EV/EBITDA, and the 155.4x PCF all price a step-change in profitability that has not appeared in reported results, and the 30.3x PB is an artifact of near-zero book equity rather than franchise premium. The market is effectively paying today for management's 2029 cash targets; if those prove credible, the multiple re-rates and the stock is undervalued, but if slippage continues, the current price is a value trap. Net verdict: fairly valued to modestly undervalued on sales, expensive on earnings and cash — a binary execution bet rather than a clear mispricing.
From a pure risk/reward standpoint, BA offers an asymmetric but unproven setup: the $233.35 average analyst target implies +34.6% upside from $173.31, and 25 of 26 analysts rate it Buy with zero Sells, yet the downside to the $157.00 low target is only about -9.4%, and a severe de-rating toward the 20-30% drawdown range is plausible if deliveries slip again. The catch is that the upside is entirely contingent on a cash-flow inflection that has repeatedly moved to the right — trailing free cash flow is still -$1.54B and interest expense of $573M exceeds operating income of $139M. The stock is therefore a good buy only for investors who can tolerate volatility (beta 1.331) and a multi-year wait, and who size positions for a possible break below $165.01. For those investors, accumulating near the low end of the 52-week range with a 2-3 year horizon is defensible; for anyone needing near-term earnings or income (0.20% yield), it is not.
BA is fundamentally a long-term holding, not a trading vehicle, because the entire thesis rests on a 2027-2029 cash-flow inflection that cannot be validated quarter to quarter. The stock is in a confirmed downtrend — down 27.84% over three months versus SPY's -2.01%, with relative strength of -25.83% — and sits at just 9.3% of its 52-week range with no sign of capitulation, so short-term traders face a falling-knife setup with a beta of 1.331 amplifying moves. The dividend yield of 0.20% offers essentially no income support, and earnings visibility is poor given trailing EPS of $0.0135 versus a forward estimate of $11.95. A minimum holding period of 2-3 years is appropriate to give the MAX 10 ramp, delivery cadence, and free cash flow inflection time to materialize; investors should size positions for a possible retest of $165.01 and avoid leverage given the 9.98x debt-to-equity and negative free cash flow.